Shanpeng Li
Staff Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Despite the success of the CD19 × CD3 T-cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed 267 adult patients with B-ALL treated with blinatumomab and used next-generation sequencing to identify molecular alterations. Patients received blinatumomab for relapsed/refractory (R/R) disease (n = 150) and minimal residual disease (MRD; n = 88), upfront as induction (n = 10) or as consolidation in MRD-negative state (n = 19). In the overall cohort, 50 patients (19%) had Philadelphia chromosome (Ph)–positive ALL, 80 (30%) had Ph-like ALL, 35 (13%) had TP53 mutations (TP53m), 7 (3%) had KMT2A rearrangement, and 8 (3%) had PAX5 alterations. For patients treated for R/R ALL, the overall complete remission (CR)/CR with incomplete hematological recovery (CRi) rate was 59%. Only pretreatment high disease burden (P < .01) and active EMD (P < .01) were associated with inferior CR/CRi rate. Of 169 patients in CR/CRi after blinatumomab, 79 (47%) patients relapsed, including 22 (28%) with CD19– and 54 (68%) with CD19+ relapse. In multivariable analysis, TP53m was associated with an increased risk of CD19– relapse (hazard ratio [HR], 6.84; 95% confidence interval [CI], 2.68-17.45; P < .01). Post-blinatumomab allogeneic stem cell transplantation consolidation was associated with a lower risk of CD19– relapse (HR, 0.10; 95% CI, 0.03-0.37; P < .01) and EMD relapse (HR, 0.36; 95% CI, 0.18-0.73; P < .01). In conclusion, leukemia genetics may predict patterns of blinatumomab failure, with TP53m associated with CD19– relapse.
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (9)
Amanda Blackmon
Clinical Assistant Professor
City Of Hope National Medical Center
Willy Hugo
Associate Professor
David Geffen School of Medicine at UCLA
Jeremy G. Reynoso
University of California, Los Angeles
James Wu
Assistant Professor
David Geffen School of Medicine at UCLA
Benjamin M Ellingson
Professor
University of California, Los Angeles
Vivek Sant
University of Texas Southwestern Medical Center
Wolfgang Wick
University Hospital Heidelberg
Lu Sun
Assistant Project Scientist
University of California
Jose Tinajero
City of Hope
Make your next move.
Prepare your application
Review drafts before you send them.